Fierce Biotech February 28, 2024
With the stage set for the first psychedelic-based therapy to nab FDA approval this year, even J.P. Morgan can’t resist the allure of compelling data and wide-open markets.
“We’re actively looking and are in constant dialogue with several companies developing both psychedelic and nonpsychedelic [treatments for] mental health,” Gaurav Gupta, M.D., said in an interview Feb. 23. “To us, it’s an important space to be tracking.”
Gupta’s acknowledgment tracks with financing data, showing January was the second-highest fundraising month on record for the psychedelic sector, according to Pitchbook and reporting from the Financial Times. The data show that more than $160 million was raised across five deals, with $100 million for Lykos Therapeutics on the heels of its FDA...
Today's Sponsors
Today's Sponsor